Form 4: Boston Scientific CFO Jonathan Monson Receives Significant Equity Compensation Awards

Boston Scientific's Executive Vice President and Chief Financial Officer, Jonathan Monson, was granted 8,350 Restricted Stock Units and options to purchase 22,173 shares of common stock, effective July 1, 2025, as part of his compensation package.

Summary

• Jonathan Monson, the Executive Vice President and Chief Financial Officer of Boston Scientific Corp (BSX), received new equity awards.
• The awards include 8,350 Restricted Stock Units (RSUs), each representing a commitment to issue one share of Boston Scientific common stock.
• Also granted were options to purchase 22,173 shares of common stock.
• The exercise price for the stock options is $104.78 per share.
• Both the Restricted Stock Units and stock options were granted on July 1, 2025.
• Both awards will vest in four equal annual installments, with the first installment occurring on July 1, 2026.

Sentiment

Score: 7

Explanation: The granting of significant equity awards to a key executive like the CFO is generally a positive signal, indicating management alignment with shareholder interests and a commitment to long-term performance and retention.

Positives

• The granting of significant equity awards to a key executive like the CFO aligns management's interests directly with those of shareholders.
• These awards serve as a strong incentive for the executive to contribute to the company's long-term performance and shareholder value creation.
• The equity grants indicate a commitment to retaining key leadership within the company.

Future Outlook

The vesting schedule for the equity awards, extending over four years, indicates a long-term retention strategy for the Executive Vice President and Chief Financial Officer, aligning his future performance with the company's sustained growth.

Industry Context

Equity compensation, including Restricted Stock Units and stock options, is a standard and widely adopted practice across the medical technology and broader corporate sectors. It serves as a critical tool for attracting, retaining, and incentivizing senior executives by aligning their financial interests with the long-term performance and strategic objectives of the company.

Comparison to Industry Standards

• Equity grants of this nature and size are common for senior executives in large medical device companies, comparable to practices at peers such as Medtronic, Abbott Laboratories, and Johnson & Johnson.
• The four-year vesting schedule for both RSUs and stock options is a standard industry practice designed to ensure executive retention and incentivize sustained performance over a multi-year horizon.
• The use of both RSUs (full value shares) and stock options (leveraged upside) is a balanced approach to executive compensation, frequently observed in the industry to provide both retention value and performance-based incentives.

Stakeholder Impact

• Shareholders: The equity grants align the financial interests of a key executive with those of shareholders, potentially leading to improved long-term value creation.
• Employees: May signal stability in leadership and a commitment to executive retention, which can positively influence overall employee morale and confidence.

Next Steps

• The Restricted Stock Units and Stock Options will begin vesting in four equal annual installments starting on July 1, 2026.

Key Dates

Keywords

Boston Scientific, BSX, Jonathan Monson, EVP and CFO, Restricted Stock Units, Stock Options, Equity Compensation, Insider Transaction, SEC Form 4, Executive Compensation